DelveInsight said the CAR T-cell therapy market for acute lymphoblastic leukemia across the 7MM was worth USD 3.2 billion in 2025, with about 12,000 incident cases and the United States as the largest market, and it said launches of candidates including lasme-cel, WU-CART-007, CTD402, obe-cel, AUTO1/22, FT839 and PMB-101 could reshape the market over 2025-2034. The report cited technology improvements, demand in relapsed or refractory ALL, durable responses and a strong clinical pipeline as growth drivers, while highlighting milestones such as FDA RMAT designation for lasme-cel in June 2026 and Orphan Drug Designation for CTD402 in January 2026. The newer topic, however, describes a separate ResearchAndMarkets forecast on ataxia telangiectasia, including EryDex and IB1001, and appears to be a mismatched record rather than an update to the same ALL CAR T-cell story.